Moxifloxacin (Avelox)

Moxifloxacin (Avelox)

C difficile risk
Oral Bioavailability
PO ~$1.50/day; IV ~$14.00/day


400mg PO daily

400mg IV daily

No dosage adjustment necessary

However, use with caution in this patient population secondary to the risk of QT prolongation

No renal adjustment necessary

General Information

  • Pneumonia including CAP, HAP, aspiration
  • Some intra-abdominal infections
  • CNS infections

Monitor QTc in patients with increased risk.

  • QTc prolongation
  • Dysglycemia
  • Rash
  • Tendinopathy and rupture
  • GI upset
  • Weakness exacerbation in myasthenia gravis
  • CNS toxicity including confusion, psychosis

  • QTc prolongation - Increased risk with other agents that prolong QTc
  • Divalent cations including Ca, Mg - Decreased absorption
  • Warfarin - Increased INR
  • Rifampin - Decrease moxifloxacin levels

Antimicrobial class: Fluoroquinolone

Pregnancy category: C

Average serum half life: 12 hours

Urine penetration: Poor

Lung penetration: Therapeutic

CSF penetration: Therapeutic

Biliary penetration: Therapeutic